Ad
related to: timolol maleate 0.5% side effects in women over 40 50 70 years
Search results
Results From The WOW.Com Content Network
However, there are short-term escape and long-term drift effects in some people. That is, tolerance develops. It may reduce the extent of the daytime IOP curve up to 50%. The IOP is higher during sleep. Efficacy of timolol in lowering IOP during the sleep period may be limited. [16] [17] [18] It is a 5–10× more potent beta blocker than ...
Dorzolamide/timolol, sold under the brand name Cosopt among others, is a medication used to treat high pressure inside the eye including glaucoma. [3] [5] [6] It is a combination of dorzolamide hydrochloride and timolol maleate. [3] It may be used when a beta blocker, like timolol, is not sufficient alone. [7] It is used as an eye drop. [3]
Two prospective, randomized, double-blinded, phase III clinical trials were conducted at 53 sites in the United States to compare the IOP-lowering efficacy and safety of 0.2% brimonidine tartrate/0.5% timolol maleate fixed combination twice daily with 0.2% brimonidine tartrate three times daily or 0.5% timolol maleate twice daily in patients ...
[4] [5] It is also available in the fixed-dose combination medication brimonidine/timolol along with timolol maleate. [6] Common side effects when used in the eyes include itchiness, redness, and a dry mouth. [4] Common side effects when used on the skin include redness, burning, and headaches. [5]
Travoprost/timolol, ... It contains travoprost and timolol maleate. [4] It was approved for medical use in the European Union in April 2006. [4] References
Topical apraclonidine can also decrease IOP in glaucoma patients by increasing trabecular outflow, in a similar way to clonidine, [1] but without the cardiovascular side effects. Apraclonidine has been compared with other treatments such as brimonidine and pilocarpine in preventing IOP spikes after laser trabeculoplasty . [ 2 ]
These side effects may occur in as many as 90% of men treated with bicalutamide monotherapy, [29] but gynecomastia is generally reported to occur in 70 to 80% of patients. [30] In the EPC trial, at a median follow-up of 7.4 years, breast pain and gynecomastia respectively occurred in 73.6% and 68.8% of men treated with 150 mg/day bicalutamide ...
The risk was highly age-dependent, with a rate of VTE of 2.1% in those less than 40 years of age and of 12% in those over 40 years of age. [161] In a subsequent study of 816 transgender women in whom the same regimen was used but transdermal estradiol had become the standard therapy for those over the age of 40, the risk of VTE was still ...